CA2564324A1 - Poudres sechees par pulverisation contenant au moins un derive de saccharose a liaison o en 1,4 et procedes de realisation associes - Google Patents

Poudres sechees par pulverisation contenant au moins un derive de saccharose a liaison o en 1,4 et procedes de realisation associes Download PDF

Info

Publication number
CA2564324A1
CA2564324A1 CA002564324A CA2564324A CA2564324A1 CA 2564324 A1 CA2564324 A1 CA 2564324A1 CA 002564324 A CA002564324 A CA 002564324A CA 2564324 A CA2564324 A CA 2564324A CA 2564324 A1 CA2564324 A1 CA 2564324A1
Authority
CA
Canada
Prior art keywords
around
spray
powder
dried powder
fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002564324A
Other languages
English (en)
Inventor
Richard Fuhrherr
Stefan Bassarab
Karoline Bechtold-Peters
Wolfgang Friess
Patrick Garidel
Torsten Schultz-Fademrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2564324A1 publication Critical patent/CA2564324A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
CA002564324A 2004-05-10 2005-05-04 Poudres sechees par pulverisation contenant au moins un derive de saccharose a liaison o en 1,4 et procedes de realisation associes Abandoned CA2564324A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004022926.0 2004-05-10
DE102004022926A DE102004022926A1 (de) 2004-05-10 2004-05-10 Sprühgetrocknete Pulver enthaltend zumindest ein 1,4 O-verknüpftes Saccharose-Derivat und Verfahren zu deren Herstellung
PCT/EP2005/004806 WO2005112892A1 (fr) 2004-05-10 2005-05-04 Poudres sechees par pulverisation contenant au moins un derive de saccharose a liaison o en 1,4 et procedes de realisation associes

Publications (1)

Publication Number Publication Date
CA2564324A1 true CA2564324A1 (fr) 2005-12-01

Family

ID=34966513

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002564324A Abandoned CA2564324A1 (fr) 2004-05-10 2005-05-04 Poudres sechees par pulverisation contenant au moins un derive de saccharose a liaison o en 1,4 et procedes de realisation associes

Country Status (7)

Country Link
EP (1) EP1778188A1 (fr)
JP (1) JP2007536313A (fr)
KR (1) KR20070037441A (fr)
CA (1) CA2564324A1 (fr)
DE (1) DE102004022926A1 (fr)
TW (1) TW200605917A (fr)
WO (1) WO2005112892A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
CN101304970A (zh) * 2005-12-21 2008-11-12 卫材R&D管理有限公司 1，2-二氢吡啶化合物的无定形物
EP2077132A1 (fr) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispositif distributeur, dispositif de stockage et procédé pour la distribution d'une formulation
CA2744655A1 (fr) * 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh Nouveaux medicaments sous forme de poudre cristalline a inhaler
WO2010112358A2 (fr) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh Procédé de revêtement d'une surface d'un composant
JP5763053B2 (ja) 2009-05-18 2015-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アダプタ、吸入器具及びアトマイザ
EA026241B1 (ru) 2009-11-25 2017-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Распылитель
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
JP5874724B2 (ja) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
WO2012130757A1 (fr) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Appareil médical pourvu d'un récipient
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (fr) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Pulvérisateur comprenant des moyens de détrompage
US9744313B2 (en) 2013-08-09 2017-08-29 Boehringer Ingelheim International Gmbh Nebulizer
EP2835146B1 (fr) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Atomiseur
DK3139979T3 (da) 2014-05-07 2023-10-09 Boehringer Ingelheim Int Enhed, forstøver og fremgangsmåde
NZ724449A (en) 2014-05-07 2022-01-28 Boehringer Ingelheim Int Nebulizer and container
EP3139984B1 (fr) 2014-05-07 2021-04-28 Boehringer Ingelheim International GmbH Nébuliseur
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5012272A (fr) * 1973-06-01 1975-02-07
DE69111271T2 (de) * 1990-03-08 1996-02-22 Ensuiko Sugar Refining Verfahren zur Herstellung eines Pulvers/mit erhöhtem Gehalt an Lactosucrose und Verwendung dieses Pulvers.
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
JPH0776527A (ja) * 1993-06-28 1995-03-20 Hayashibara Biochem Lab Inc 半固形製剤とその製造方法
AU699715B2 (en) * 1994-01-31 1998-12-10 Astellas Pharma Inc. Intrabuccally dissolving compressed moldings and production process thereof
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US5922324A (en) * 1995-01-31 1999-07-13 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Propolis extract with improved water-solubility
US5892026A (en) * 1995-04-12 1999-04-06 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo High Trehalose content syrup
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
DE19732351A1 (de) * 1997-07-28 1999-02-04 Hoechst Ag Verfahren zur Herstellung der Süßkraft und zur Geschmacksverbesserung einer Mischung hochintensiver Süßstoffe
AU2002241723A1 (en) * 2000-12-21 2002-07-24 Inhale Therapeutic Systems, Inc. Storage stable powder compositions of interleukin-4 receptor

Also Published As

Publication number Publication date
JP2007536313A (ja) 2007-12-13
WO2005112892A1 (fr) 2005-12-01
KR20070037441A (ko) 2007-04-04
DE102004022926A1 (de) 2005-12-15
EP1778188A1 (fr) 2007-05-02
TW200605917A (en) 2006-02-16

Similar Documents

Publication Publication Date Title
US7723306B2 (en) Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) Powder comprising new compositions of oligosaccharides and methods for their preparation
CA2564324A1 (fr) Poudres sechees par pulverisation contenant au moins un derive de saccharose a liaison o en 1,4 et procedes de realisation associes
US7611709B2 (en) 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US20050191246A1 (en) Powders comprising low molecular dextran and methods of producing those powders
EP1789019B1 (fr) Poudres contenant de nouveaux melanges d'oligosaccharides et procedes de realisation associes
CA2548132A1 (fr) Poudre contenant un dextrane de faible poids moleculaire et procede de fabrication associe
US20070298116A1 (en) Amorphous, spray-dried powders having a reduced moisture content and a high long term stability
JP2007536314A (ja) 抗体又は抗体誘導体を安定化させるための１，４ｏ−結合型サッカロース誘導体
EP1666028B1 (fr) Compositions de poudre sèche à dispersivité ameliorée
CA2654264C (fr) Poudre pour inhalation contenant de la phenylalanine

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued